Pharma Deals Review, Vol 2008, No 94 (2008)

Font Size:  Small  Medium  Large

Dyax and Cubist Sign Deal for DX-88 Surgical Indications

Helen Scrutton

Abstract


This article discusses Dyax and Cubist Pharmaceuticals’ recent deal for Dyax’s DX-88 (ecallantide), a Phase II product for the prevention of blood loss during surgery in North America and Europe.

Full Text: pdf html

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.